Applicants,Chemical_Name,Funding_requested_for,Pharmaceutical,Priority_List,Schedules,Therapeutic_group
GLAXOSMITHKLINE NZ LIMITED,Recombinant Zoster Vaccine,"Prevention of herpes zoster in adults aged 66 to 74 years, plus catch up for those aged 75 years and over",Recombinant Zoster Vaccine (SHINGRIX),Options for investment,Community and Hospital,
